NASDAQ:ABMD - ABIOMED Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $315.04 -8.17 (-2.53 %) (As of 03/25/2019 01:46 PM ET)Previous Close$323.21Today's Range$313.55 - $322.0152-Week Range$274.02 - $459.75Volume14,911 shsAverage Volume408,972 shsMarket Capitalization$14.21 billionP/E Ratio128.51Dividend YieldN/ABeta0.37 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. In addition, the company is involved in the development of Impella 5.5 and Impella BTR that are percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump, a device for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. Receive ABMD News and Ratings via Email Sign-up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:ABMD Previous Symbol CUSIP00365410 CIK815094 Webwww.abiomed.com Phone978-646-1400Debt Debt-to-Equity RatioN/A Current Ratio6.76 Quick Ratio5.99Price-To-Earnings Trailing P/E Ratio128.51 Forward P/E Ratio88.00 P/E Growth3.26 Sales & Book Value Annual Sales$593.75 million Price / Sales23.92 Cash Flow$2.7114 per share Price / Cash Flow116.19 Book Value$15.57 per share Price / Book20.23Profitability EPS (Most Recent Fiscal Year)$2.45 Net Income$112.17 million Net Margins30.12% Return on Equity20.31% Return on Assets18.03%Miscellaneous Employees1,143 Outstanding Shares45,090,000Market Cap$14.21 billion Next Earnings Date5/2/2019 (Estimated) OptionableOptionable ABIOMED (NASDAQ:ABMD) Frequently Asked Questions What is ABIOMED's stock symbol? ABIOMED trades on the NASDAQ under the ticker symbol "ABMD." How were ABIOMED's earnings last quarter? ABIOMED, Inc. (NASDAQ:ABMD) announced its quarterly earnings results on Thursday, January, 31st. The medical equipment provider reported $0.97 EPS for the quarter, beating analysts' consensus estimates of $0.94 by $0.03. The medical equipment provider earned $200.56 million during the quarter, compared to analyst estimates of $200.60 million. ABIOMED had a return on equity of 20.31% and a net margin of 30.12%. View ABIOMED's Earnings History. When is ABIOMED's next earnings date? ABIOMED is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for ABIOMED. What guidance has ABIOMED issued on next quarter's earnings? ABIOMED updated its FY 2019 earnings guidance on Thursday, January, 31st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $780-780 million, compared to the consensus revenue estimate of $774.79 million. What price target have analysts set for ABMD? 5 brokers have issued 1 year target prices for ABIOMED's shares. Their predictions range from $332.00 to $480.00. On average, they anticipate ABIOMED's share price to reach $426.60 in the next twelve months. This suggests a possible upside of 35.4% from the stock's current price. View Analyst Price Targets for ABIOMED. What is the consensus analysts' recommendation for ABIOMED? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ABIOMED. Has ABIOMED been receiving favorable news coverage? Media stories about ABMD stock have trended positive on Monday, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ABIOMED earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. Who are some of ABIOMED's key competitors? Some companies that are related to ABIOMED include Boston Scientific (BSX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Hill-Rom (HRC), Insulet (PODD), Penumbra (PEN), Integra Lifesciences (IART), ICU Medical (ICUI), Globus Medical (GMED), Novocure (NVCR), Haemonetics (HAE) and Tandem Diabetes Care (TNDM). What other stocks do shareholders of ABIOMED own? Based on aggregate information from My MarketBeat watchlists, some companies that other ABIOMED investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Align Technology (ALGN), Netflix (NFLX), Adobe (ADBE), Paypal (PYPL), salesforce.com (CRM), Mastercard (MA) and Boeing (BA). Who are ABIOMED's key executives? ABIOMED's management team includes the folowing people: Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 52)Dr. David M. Weber, Chief Operating Officer (Age 58)Mr. Michael G. Howley, VP & GM of Global Sales (Age 55)Mr. William J. Bolt, Sr. VP of Global Quality, Regulatory & Clinical Operations (Age 67)Mr. Ian McLeod, VP & Corp. Controller Who are ABIOMED's major shareholders? ABIOMED's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.02%), Baillie Gifford & Co. (2.37%), MERIAN GLOBAL INVESTORS UK Ltd (1.43%), Geode Capital Management LLC (1.35%), Bank of New York Mellon Corp (1.09%) and Norges Bank (1.08%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Martin P Sutter, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED. Which institutional investors are selling ABIOMED stock? ABMD stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Two Sigma Advisers LP, Eagle Asset Management Inc., Bank of New York Mellon Corp, Nisa Investment Advisors LLC, State Treasurer State of Michigan, Penserra Capital Management LLC and Scout Investments Inc.. Company insiders that have sold ABIOMED company stock in the last year include Andrew J Greenfield, David M Weber, Martin P Sutter, Michael G Howley, Michael R Minogue and William J Bolt. View Insider Buying and Selling for ABIOMED. Which institutional investors are buying ABIOMED stock? ABMD stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Baillie Gifford & Co., 1832 Asset Management L.P., AGF Investments Inc., Frontier Capital Management Co. LLC, Amundi Pioneer Asset Management Inc., Retirement Systems of Alabama and BlackRock Inc.. View Insider Buying and Selling for ABIOMED. How do I buy shares of ABIOMED? Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is ABIOMED's stock price today? One share of ABMD stock can currently be purchased for approximately $315.04. How big of a company is ABIOMED? ABIOMED has a market capitalization of $14.21 billion and generates $593.75 million in revenue each year. The medical equipment provider earns $112.17 million in net income (profit) each year or $2.45 on an earnings per share basis. ABIOMED employs 1,143 workers across the globe. What is ABIOMED's official website? The official website for ABIOMED is http://www.abiomed.com. How can I contact ABIOMED? ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected] MarketBeat Community Rating for ABIOMED (NASDAQ ABMD)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 440 (Vote Outperform)Underperform Votes: 373 (Vote Underperform)Total Votes: 813MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote "Outperform" if you believe ABMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABMD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/25/2019 by MarketBeat.com StaffFeatured Article: How are institutional investors different from individual investors?